India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins
Executive Summary
India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.
You may also be interested in...
Has India’s Drug Pricing Authority Been Rendered Toothless?
India has put in place a new panel to act as a 'recommending body' to the National Pharmaceutical Pricing Authority, raising questions about the pricing body’s autonomy and whether its role has been 'usurped'. The pharma industry claims a balanced pricing regime may emerge under the new system but doesn’t rule out inter-department conflicts in the government.
New Window: India Extends Price Cap Exemption To Foreign Innovation
Innovative medicines developed abroad and patented and launched in India could be entitled to unfettered pricing for a five-year period under new norms announced in the country. Orphan drugs could also qualify for such exemption, much to the concern of healthcare activists.
Abbott Exits Indian Industry Group: Fault Lines Showing?
Abbott’s unexpected decision to move out of the Organization of Pharmaceutical Producers of India (OPPI), the premier multinational industry body in India, has provided enough grist to the rumor mill to work overtime. Experts tell Scrip where the divisive issues may lie.